Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1-937-G variant

O Obazee; C Justenhoven; S Winter; J Chang-Claude; A Rudolph; P Seibold; D Flesch-Janys; U Hannelius; J Li; K Humphreys; P Hall; G Giles; G Severi; L Baglietto; M Southey; S Rabstein; V Harth; A Lotz; B Pesch; T Brüning; C Baisch; YD Ko; U Hamann; H Brauch

Journal article

Confirmation of the reduction of hormone replacement therapy-related breast cancer risk for carriers of the HSD17B1-937-G variant

O Obazee, C Justenhoven, S Winter, J Chang-Claude, A Rudolph, P Seibold, D Flesch-Janys, U Hannelius, J Li, K Humphreys, P Hall, G Giles, G Severi, L Baglietto, M Southey, S Rabstein, V Harth, A Lotz, B Pesch, T Brüning Show all

Breast Cancer Research and Treatment | SPRINGER | Published : 2013

DOI: 10.1007/s10549-013-2448-7

Download PDF

Abstract

17β-hydroxysteroid dehydrogenase type 1 (HSD17B1) plays an important role in the biosynthesis of 17β-estradiol. The current study aimed at confirming the reduced risk of breast cancer in carriers of the non-synonymous HSD17B1-937-A>G (rs605059) polymorphism who used any hormone replacement therapy (HRT) for 10 years or longer. We performed an independent association study using four breast cancer case-control studies from Australia, Germany, and Sweden. In all, 5,777 cases and 8,189 age-matched controls of European descent were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and TaqMan. Risk estimates were calculated by interaction ana..

View full abstract

University of Melbourne Researchers

Graham Giles Author

Melissa Southey Author

Related Projects (4)

Epidemiology of chronic disease, health interventions and DNA studies

PLATYPUS

This proposal builds on the applicants’ experience with existing large prospective studies and on studies of families of patients with bowel..

THE HEALTH 2020 COHORT STUDY (HEALTH 2020)

Our aim is to develop appropriate infrastructures necessary to facilitate access by researchers to the accumulated data, including questionn..

Grants

Awarded by Robert Bosch Stiftung

Funding Acknowledgements

The authors acknowledge support of the Robert Bosch Foundation, Stuttgart, Germany, and the Federal Ministry of Education and Research (BMBF) Germany grants 01KW9975/5, 01KW9976/8, 01KW9977/0, 01KW0114. OO was supported by the 7FP EU Marie Curie Initial Training Network "FightingDrugFailure'' (GA238132). The MARIE study was supported by the Deutsche Krebshilfe e.V., grant number 70-2892-BR I and the Hamburg Cancer Society. The MARIE-GENICA project was funded by BMBF Germany grants 01KH0401, 01KH0402, 01KH0410, and 01KH0411. SASBAC was supported by National Institutes of Health (RO1 CA58427) and Marit and Hans Rausing's Initiative Against Breast Cancer. KC was supported by the Swedish Cancer Society (5128-B07-01PAF). MCCS is supported by Cancer Council Victoria and by NHMRC (grants 209057, 251533, 396414, 504711, and 504715).